ClinicalTrials.gg
RecruitingNCT06938412EASE-AFUpdated Nov 13, 2026

Exercise Activity Intervention With Sensor-Based Engagement in Patients With Atrial Fibrillation

An interventional study of Physical Activity Intervention Using FitBit Wearable Device in Atrial Fibrillation, Arrhythmias, Cardiac and Cardiovascular Diseases, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 13, 2026Eligibility revisedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Planned enrollment
343rd of 679
120 · median 127
Started
2026
with 47 others
No phase
405 of 993
67 open now
Primary completion
2028-03
later than 160 of 219 live
Registered
925th of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 343rd largest by planned enrollment of the 679 interventional ones that give a count, is one of 48 that started in 2026, is one of 405 with no phase, reaches primary completion later than 160 of the 219 other live ones, and was the 925th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

154 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

Atrial fibrillation (AF) affects 1 in 4 individuals during their lifetime and continues to increase in frequency and impact. Exercise intervention has established benefits to improve AF symptoms and burden in clinical studies. However, lack of access to exercise programs has limited therapeutic adoption. The growth of technology-driven health care and diagnostics, recognized as an emerging priority by the American Heart Association, offers an opportunity for a pragmatic and patient-centered approach to meet this need. EASE-AF is a prospective, interventional study with a sequential run-in control to evaluate if a digital health-driven, patient-centered exercise intervention improves AF symptoms and burden. The research team will enroll 120 patients with symptomatic, non-permanent AF. The main impact of this study will be the establishment of evidence for a novel, pragmatic paradigm for a patient-centered, digital technology-driven personalized exercise intervention for patients with AF.

03

Conditions studied

  • Atrial Fibrillation
  • Arrhythmias, Cardiac
  • Cardiovascular Diseases

Keywords

  • Atrial Fibrillation
  • Physical Activity
  • Exercise
  • Digital Health Intervention
  • Wearable Technology
  • Symptoms
  • Quality of Life
04

Who can participate

The criteria were revised on the registry on Nov 13, 2026. See what changed

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥40years of age
  • non-permanent AF
  • Electrocardiographic (or equivalent) documentation of AF within 36 months (would need to have evidence of AF after initial post-ablation blanking period if the patient had prior AF ablation)
  • AF Severity Scale (AFSS) symptom score 6-26
  • Self-report weekly moderate-vigorous physical activity (MVPA) \< 150 minutes

Exclusion criteria

Exclusion Criteria:

  • Unable to give consent
  • ≤90 days from AF ablation, coronary revascularization, heart failure hospitalization
  • (LVEF) \<40%, moderate to severe stenotic valvular heart disease or severe regurgitant valvular disease or history of mechanical valve replacement, presence of implanted pacemaker or defibrillator system
  • Labile or unable to take anticoagulant despite indication
  • \< 1 year
  • Hemodialysis; severe pulmonary or liver disease
  • Musculoskeletal, balance/gait issues, severe peripheral vascular disease, or neuropathy or other neurologic conditions limiting exercise
  • Upon initial screening, if the participant's baseline FitBit-measured MVPA ≥180 minutes/week (despite self-report range of \<150 minutes), the participant will be further excluded.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Patients With Atrial Fibrillation

    Patients with symptomatic, non-permanent AF.

    Device: Physical Activity Intervention Using FitBit Wearable Device

Interventions

  • DevicePhysical Activity Intervention Using FitBit Wearable Device

    The intervention is a digital technology-driven, patient-centric approach to physical activity and exercise intervention with tailored digital engagement and progressive physical activity goals (the intervention). The intervention will be conducted using FitBit wearable device.

06

What researchers measure

Primary outcomes

  1. Atrial Fibrillation Severity Scale (AFSS), Symptom Severity Domain

    The Symptom Severity domain (Part C) of the validated Atrial Fibrillation Severity Scale (AFSS) questions patients regarding the severity of 7 AF-related symptoms (on scale of 0-5 per question, 5 denoting a great deal of symptom and 0 with no symptom) over the preceding 4-week period. Total scores range 0-35 on the Symptom Severity Domain of the Atrial Fibrillation Severity Scale (AFSS), higher score denotes more severe AF-related symptoms.

    Time frame: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period

Secondary outcomes

  1. Atrial Fibrillation Severity Scale (AFSS)

    The full Atrial Fibrillation Severity Scale (AFSS) is composed of 19-items, investigating four domains: global well-being, symptom burden, health care utilization, symptom severity. Global well-being: 1-10; 10 denotes best possible quality of life. Symptom burden: Composite of AF burden as AF duration + AF frequency + AF severity; ranging 0-30, higher denotes more symptom burden. Health care utilization: ER visits (0-7, higher number denotes more utilization), Hospitalizations (0-7, higher number denotes more utilization), Specialist visits (0-7, higher number denotes more utilization); Symptom Severity: 0-35, higher score denotes more severe AF-related symptoms

    Time frame: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period

  2. AF Arrhythmia Burden: Percentage of time in AF

    Global AF arrhythmia burden will be measured as percentage of time in AF measured during an 8-14-day monitoring period at the end of each time point as quantified by either clinically validated patch-based monitoring system or loop recorder.

    Time frame: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period

  3. AF Arrhythmia Burden: Duration of longest AF Arrhythmia Episode

    Duration of the longest AF episode during the monitoring period will be quantified by either clinically validated patch-based monitoring system or loop recorder.

    Time frame: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period

  4. Weekly Step Counts

    Weekly step counts measured by FitBit wearable device provided by the study

    Time frame: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period

  5. Weekly Exercise Minutes

    Weekly exercise minutes measured by FitBit wearable device provided by the study

    Time frame: Baseline, End of 4-week Run-in Control Period, End of 24-week Physical Activity Intervention Period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Not planning to share individual participant data. Aggregate data will be shared instead.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Mar 2028, 19 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 19 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
Apr 22, 2025
StartActual
Aug 11, 2026
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Minimum age 18 Years→40 Years; 4 inclusion criteria edited; 2 exclusion criteria edited, 1 removed
What changed in the criteria
Inclusion criteria
  • ChangedBefore Paroxysmal AFNow non-permanent AF
  • EditedElectrocardiographic (or equivalent) documentation of AF within 1236 months (would need to have evidence of AF after initial post-ablation blanking period if the patient had prior AF ablation)
  • EditedAF Severity Scale (AFSS) symptom score 136-26
  • EditedSelf-report weekly moderate-vigorous physical activity (MVPA) 30-120< 150 minutes
Exclusion criteria
  • EditedLeft ventricular ejection fraction (LVEF) <5040%, moderate to severe stenotic valvular heart disease or severe regurgitant valvular disease or history of mechanical valve replacement, presence of implanted pacemaker or defibrillator system
  • RemovedSelf-report MVPA <30 minutes
  • EditedUpon initial screening, if the participant's baseline FitBit-measured MVPA ≥180 minutes/week (despite self-report range of 30-120<150 minutes), the participant will be further excluded.
Nov 13, 2026
Contact
Study contact changed: E•••@mountsinai.org · •••3506→J•••@mountsinai.org · •••7077; J•••@mountsinai.org→E•••@mountsinai.org; none listed→•••1674. See the current contact
Nov 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Icahn School of Medicine at Mount Sinai · New York, United StatesContact k•••@mssm.edu→E•••@mountsinai.orgContact removed f•••@mountsinai.org
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Eligibility Minimum age 18 Years→40 Years; 4 inclusion criteria edited; 2 exclusion criteria edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • ChangedBefore Paroxysmal AFNow non-permanent AF
    • EditedElectrocardiographic (or equivalent) documentation of AF within 1236 months (would need to have evidence of AF after initial post-ablation blanking period if the patient had prior AF ablation)
    • EditedAF Severity Scale (AFSS) symptom score 136-26
    • EditedSelf-report weekly moderate-vigorous physical activity (MVPA) 30-120< 150 minutes
    Exclusion criteria
    • EditedLeft ventricular ejection fraction (LVEF) <5040%, moderate to severe stenotic valvular heart disease or severe regurgitant valvular disease or history of mechanical valve replacement, presence of implanted pacemaker or defibrillator system
    • RemovedSelf-report MVPA <30 minutes
    • EditedUpon initial screening, if the participant's baseline FitBit-measured MVPA ≥180 minutes/week (despite self-report range of 30-120<150 minutes), the participant will be further excluded.
    Contact Study contact changed: E•••@mountsinai.org · •••3506→J•••@mountsinai.org · •••7077; J•••@mountsinai.org→E•••@mountsinai.org; none listed→•••1674. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Icahn School of Medicine at Mount Sinai · New York, United StatesContact k•••@mssm.edu→E•••@mountsinai.orgContact removed f•••@mountsinai.org
    + 2 other changes: description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06938412
Collaborators
American Heart Association
Responsible party
Janice.Chyou (Assistant Clinical Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Apr 22, 2025
Start date
Aug 11, 2026
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Jaclyn Printz
Contact
EASE-AF@mountsinai.org
917-991-674
Jaclyn Printz
Contact
Jaclyn.Printz@mountsinai.org
212-824-7077
Janice Y Chyou, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion